As Hospital Professional News was going to press, a seminar hosted in Dublin by the Health Products Regulatory Authority (HPRA) heard that a key priority for its post-Brexit strategies is to safeguard against disruption to Irish patients’ access to medicines.
The HPRA stated that it is looking at a number of potential scenarios that seek to ensure continued availability of health products to Ireland. The event, attended by over 300 representatives from the biopharma, medtech and life sciences sector, discussed the concerns of different stakeholder groups given the unique context for Ireland in the Europe-wide medicine regulatory environment.
For verified healthcare professionals
Log in or register for free to read this article. HPN is for healthcare professionals, so new accounts are verified by our team.
